BIOLIFE SOLUTIONS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $BLFS in the last 7 days.
No SEC Form 4 filings for $BLFS in the last 30 days.
See all $BLFS insider activity →Biotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.
BioLife Solutions, Inc. (BLFS) reported Q2 2026 sales of $28.47M, up from $23.44M, and shifted from a net loss of $15.84M to net income of $45.10M. Basic EPS from continuing operations improved from -$0.32 to $0.92. The article also discusses a pending $1.6B Repligen acquisition and forecasts $161.3M revenue and $33.2M earnings by 2028.
Simply Wall St reports BioLife Solutions (BLFS) swung from a prior net loss to net income of $45.1 million in Q2, with sales of $28.47 million, after its 6 Aug 2026 earnings report. The stock rose 22.97% over 30 days and 69.70% over 90 days. The article cites BLFS trading at a 35x P/E versus a SWS fair P/E of 15.6x and DCF value of $38.22 (about 7.8% above $35.23).
Recent BLFS coverage spans earnings, mergers & acquisitions and financial news.
M&A headline is a direct catalyst that can tighten spreads and drive takeover-arb behavior, subject to deal terms and regulatory/closing risk.
The article frames a sharp profitability turnaround and links it to investor narrative around the pending Repligen acquisition.
The article frames BLFS as recently profitable with a multiple reset, but highlights execution and earnings-stability risk behind the still-elevated P/E.
Earnings show a profitability inflection, but the article frames the market as already discounting the shift while a pending Repligen deal adds deal-risk.
The earnings and revenue beats create a near-term catalyst, but the article flags that follow-through depends on management commentary and updated estimate revisions.
alphai scores every news story that mentions BLFS with an AI model for sentiment and relevance, and aggregates insider trades from BIOLIFE SOLUTIONS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.
5 min readBioLife Solutions, Inc. (BLFS) reported Q2 2026 sales of $28.47M, up from $23.44M, and shifted from a net loss of $15.84M to net income of $45.10M. Basic EPS from continuing operations improved from -$0.32 to $0.92. The article also discusses a pending $1.6B Repligen acquisition and forecasts $161.3M revenue and $33.2M earnings by 2028.
6 min readSimply Wall St reports BioLife Solutions (BLFS) swung from a prior net loss to net income of $45.1 million in Q2, with sales of $28.47 million, after its 6 Aug 2026 earnings report. The stock rose 22.97% over 30 days and 69.70% over 90 days. The article cites BLFS trading at a 35x P/E versus a SWS fair P/E of 15.6x and DCF value of $38.22 (about 7.8% above $35.23).
6 min readBioLife Solutions (BLFS) reported Q2 results showing a swing to profitability, with revenue of about $28.47M versus $25.42M a year earlier. Net income rose to about $45.10M from a $15.84M loss, and basic EPS turned to about $0.92 from a loss of $0.33. The stock rose about 2% on the day, amid a pending Repligen deal at $31.00/share.
6 min readBioLife Solutions, Inc. (BLFS) reported Q2 adjusted EPS of $0.04, versus a Zacks Consensus Estimate of a loss of $0.01. Revenue was $28.47 million, up from $25.42 million a year earlier and 1.48% above consensus. Ahead of the report, estimate revisions were favorable and the stock had a Zacks Rank #2 (Buy).
5 min readBioLife Solutions (BLFS) reported Q2 revenue of $28.5 million, compared with a FactSet estimate of $27.8 million, according to the earnings flash. The company develops cell processing tools and services for the cell and gene therapy market, including CryoStor and HypoThermosol media and related systems.
2 min readBioLife Solutions (NASDAQ: BLFS) said it plans a cash-stock merger with Repligen, according to the company. The deal terms and timing were not provided in the excerpt, but it would combine the businesses under a merger agreement.
2 min readBIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Results of Operations and Financial Condition. BioLife Solutions Reports Second Quarter 2026 Financial Results Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and n
6 min readBioLife Solutions (Nasdaq: BLFS) reported Q2 2026 revenue of $28.5 million, up 21% year over year, with GAAP gross margin of 64% and non-GAAP gross margin of 65%. GAAP net income was $45.1 million, including a $42.4 million non-cash tax benefit; non-GAAP adjusted EBITDA was $7.4 million. BioLife said Repligen will acquire it for about $1.5 billion, expected to close in Q4 2026.
4 min readRepligen agreed to acquire BioLife Solutions, a Nasdaq-listed cell therapy tools company. After the deal announcement, law firms opened investigations into whether the transaction is fair to BioLife shareholders, focusing on the sale process, conflicts, and valuation. The offer is $31.00 per share, about a 24% premium to 90-day VWAP, with 64% stock and 36% cash.
6 min read
